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Abstract 
Purpose: To determine if complexation with β- cyclodextrin (β-CD) increases water solubility and 
subsequent bioavailability of nelfinavir mesylate (NM). 
Methods: Complexation of NM with β-CD in 1:1.5 molar ratio was carried out by solvent evaporation, 
freeze-drying and kneading methods. The complexes were characterized by Fourier transform infrared 
spectroscopy (FTIR). The in vitro solubility of the pure drug as well as that of the complexes was 
evaluated using USP type 2 apparatus. One of the drug complexes was also evaluated in vivo using 
Wistar rats to determine its pharmacokinetic profile.  
Results: Freeze-dried NM-βCD complex was selected for in vivo studies based on its free flowing 
property and superior texture. The complexes prepared by the three methods all showed largely similar 
dissolution rate. The in vivo pharmacokinetic study of the freeze-dried complex in male Wistar rats 
showed significant increase in Cmax, tmax and AUC (p ≤ 0.05) compared to those of the plain drug.  
Conclusion: These findings suggest that complexation of NM with β-CD is an effective and promising 
approach to increasing the oral bioavailability of NM. 
 
Keywords: β-Cyclodextrin, Nelfinavir mesylate, Inclusion complex, Freeze-drying, Bioavailability, 
Dissolution, Kneading 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Nelfinavir mesylate (NM) is an HIV (human 
immunodeficiency virus) protease inhibitor which 
results in production of immature, non-infectious 
virus during the replication and release life cycle 
of the virus [1]. Compared to all other protease 
inhibitors, NM is usually prescribed at a higher 
than required dose of 1250 mg twice daily for 
adults [2]. A major drawback in therapeutic 
application and efficacy of NM in oral 
administration is its poor water solubility, 
resulting in poor bioavailability.  
Orally administered drugs are assigned the 
Biopharmaceutics Classification System (BCS) 
on the basis of solubility and permeability 
characteristics.  NM is a BCS class IV drug [3]. 
Efforts are in progress to increase its solubility 
and thereby NM’s bioavailability to reduce its 
dose [4]. 
  
Cyclodextrins have been extensively studied with 
the aim of improving solubility, dissolution and 
bioavailability of poorly soluble drugs. 
Cyclodextrins have an internal cavity resembling 
a truncated cone. The special feature of a 
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cyclodextrin is that its internal cavity is 
hydrophobic while the entrance of the cavity is 
hydrophilic. Due to this feature, drug molecules 
complexed with cyclodextrins have increased 
water solubility [5]. This feature can also alter the 
physicochemical properties of guest molecules 
[6]. Enhanced bioavailability with cyclodextrin is 
observed due to its drug entrapment property [7]. 
Entrapped drugs are more stable in the form of 
complexes due to this added protection from the 
external environment [8]. 
 
Of all cyclodextrins, β-CD is the most widely 
used for increasing water solubility of otherwise 
hydrophobic drugs. The ease of its synthesis and 
low price are key factors for its popularity [9].  
Cyclodextrin complexation of NM with β-CD 
using diverse methods such as solvent 
evaporation, kneading and ball milling have 
resulted in increased solubility of NM [10,11]. 
However, these studies have not addressed 
NM’s pharmacokinetic profile including 
bioavailability. The present study uses the freeze 
drying and other methods to prepare NM-βCD 
complexes, and reports the results of its water 
solubility and pharmacokinetic profile. 





Nelfinavir mesylate was received as a gift sample 
from Aurobindo Pharma, Hyderabad, India. 
Diazepam was procured from INTAS Lab Pvt 
Ltd, Ahmedabad, India. β-Cyclodextrin was 
obtained from  Hetero Labs Ltd, Bangalore, 
India. Acetonitrile and methanol (HPLC grade) 
were procured from Merck Laboratories Pvt Ltd, 
Mumbai, India. All other reagents and solvents 




The solubilities of NM and NM/β-CD mixture 
were determined between pH 1.2 and 7.4 by 
shake-flask method. For the same, an excess 
amount of NM or NM β-CD was placed in 10 ml 
vials to which 3.0 ml of different solutions (pH 
1.2, 4.5, 6.8 and 7.4) and distilled water were 
added. These vials were incubated in a shaking 
water bath (orbital shaker incubator, Remi 
Laboratory instruments, India) set at 150 rpm for 
24 h at 37 °C. Thereafter, samples were 
centrifuged in an Eppendorf Centrifuge Model 
5043 at 23,000 x g for 15 min to separate the 
solid material from the solution and analysed by 
HPLC after appropriate dilution.[12].  
 
Preparation of NM β-CD complex  
 
Inclusion complex of NM and β-CD was prepared 
in 1:1.5 molar ratio of NM and β-CD based on 
the phase solubility study reported by Vavia et al 
[11]. For the phase solubility study, excess of NM 
(in quantities exceeding its aqueous solubility) 
was added to aqueous solutions containing 
different concentrations of β-CD ranging from 2 
mM to 15 mM. The mixtures were mechanically 
stirred at 200 rpm for 48 h at room temperature 
followed by filtration through 0.2 μm filter and 
evaluated for NM content using UV 
spectrophotometry. The apparent stability 
constant K was estimated from straight line of 
phase solubility plot according to the equation of 
Higuchi and Connars (Eq 1) [13]. 
 
K = Slope/S(1-Slope) ……………………… (1)  
 
where S is the solubility of NM in the absence of 
β-CD. 
 
Co-evaporation method  
 
The complex (NC-01) was prepared in 1:1.5 
molar ratio of NM and β-CD. A solution of β-CD 
was prepared by dissolving β-CD (1702 mg) in 
water. NM (666 mg) solution was prepared in 
methanol. The NM solution and β-CD solution 
were then mixed together. The solution was 
stirred magnetically for 1 h at 70-80 ºC and dried 
to obtain a powder. The precipitated complex 
was pulverised, sieved (# 60) and stored in a 
desiccator [14,15]. 
 
Freeze-drying method  
 
The freeze-dried product (NC-02) was prepared 
by dissolving β-CD (4256 mg) in water and 
adding the stoichiometric amount of NM (1667 
mg). The resulting solution was frozen and 
freeze dried at -45 oC and 45 m Torr for 48 h.  
The lyophilized powder was stored in tightly 
sealed container inside a desiccator until use 
[16]. 
 
Kneading method  
 
β-CD (NC-03, 4256 mg) was placed in a mortar 
and wetted with ethanol-water mixture (1:1 v/v). 
Trituration was continued and it was kneaded to 
a paste consistency. NM (1667 mg) was added 
and kneaded for 60 min with successive addition 
of ethanol-water mixture to obtain the desired 
paste consistency. The formed complex was 
dried in vacuum oven for 24 h at 50 oC. Dried 
product was scraped, passed through a 60# 
mesh sieve and stored in a desiccator until 
further use [14,16,17]. 
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Fourier Transform Infrared Spectroscopy 
(FTIR) 
 
FTIR spectra of the selected complex NC-02) 
were recorded on a FTIR 8300 
Spectrophotometer (Shimadzu, Japan) by KBr 
disk method. The scanning range was 4000 to 
400 cm-1. 
 
In vitro dissolution studies 
 
In vitro dissolution studies of the plain NM and 
the complexes were carried out using USP Type 
II dissolution apparatus (Electrolab, India). 
Dissolution of powders equivalent to 10 mg of 
NM was studied in 0.1 N HCl.  Dissolution 
medium (900 ml) was taken and maintained at 
37.0 ± 5 ºC. Paddles were rotated at 50 rpm. 
Samples were removed at different time 
intervals, filtered through Whatman filter paper 
and analysed for percent drug release by HPLC. 
 
HPLC analysis of NM  
 
The analytical method for NM was developed 
and validated as per the ICH Q2 (R1) guideline 
[18]. Chromatographic separations were 
performed on a Shimadzu 10 ADVP high 
performance liquid chromatographic instrument 
with Grace Smart C 18 (250.0 × 4.6 mm, 5 µ) 
column in isocratic reverse phase mode 
integrated with UV detection at 254 nm. Mobile 
phase consisting of a mixture of acetonitrile and 
25.0 mM KH2PO4 pH 3.2 (50:50 % v/v) pumped 
at a constant flow rate 1.0 ml/min for the run time 
of 8.0 min. The injection volume was 20.0 µl.  
 
Bioanalytical method was also developed and 
validated as per ICH guidelines. The analytical 
conditions were almost similar except mobile 
phase acetonitrile and 25.0 mM KH2PO4 pH 3.2 
(45:55 % v/v) for the run time of 14.0 min and 
injection volume was 50.0 µl.  
 
Retention time for Nelfinavir as well as internal 
standard diazepam was 8.03 ± 0.01 min and 
11.45 ± 0.03 min, respectively. The column and 





A single-dose pharmacokinetic study was 
conducted in accordance with the ethical 
guidelines for investigations in laboratory animals 
and was approved by the Institutional Animal 
Ethics Committee (IAEC), Manipal University 
(MU) No: IAEC/KMC/50/2012. Male Wistar rats, 
250 ± 20 g were divided into three groups (n= 6) 
each and fasted overnight with free access to 
water for 12 h. The first group was dosed orally 
with 20.0 mg kg-1 body weight of NM suspended 
in 0.5 % (w/v) carboxyl methyl cellulose (CMC) 
aqueous solution as vehicle. The second group 
received NM-β-CD equivalent to 20.0 mg kg-1 
NM in 0.5 % CMC solution as vehicle and the 
third group received 5.0 mg kg-1 NM in 40 % v/v 
polyethylene glycol and 10 % in ethanol in water 
for injection administered intravenously to obtain 
the absolute bioavailability. Blood samples were 
collected at predetermined time intervals. Plasma 
was separated immediately by centrifugation at 
2500 x g for 10 min and frozen at -20 °C until 
analysis. 
 
Various pharmacokinetic parameters were 
calculated using WinNonlin 5.3.2. For the 
calculation of oral bioavailability the mean area 
under the plasma concentration verses time 
curves AUC0-t was compared. Absolute 
bioavailability of NM from NM-β-CD was 
obtained as in Eqs 2 -4.                     
 
F = A1D2/A2D1 …………………………….… (2) 
 
A1 = AUC 0 -∞ oral, A2 = AUC 0 – iv …….… (3) 
 
D1 = Dose oral, D2 = Dose iv  ….…………….(4) 
 
where F is the absolute bioavailability 
 
Difference in the pharmacokinetic parameters of 
NM was evaluated using unpaired t-test (p = 
0.05) with graph pad prism. Results are 
expressed as mean value ± SEM. 
 
Extraction of drug from plasma 
 
The bioanalytical method was validated as per 
FDA guidelines. The plasma concentration of NM 
was determined by RP-HPLC. Ten μL of 
diazepam (I.S.) solution (40 µg mL-1) was added 
to 90 μL plasma standard or sample followed by 
200 μL of 50 mM potassium dihydrogen 
phosphate buffer of pH 3.2. The sample was 
vortexed for 30 s and the drug was extracted by 
addition of 1.8 ml of TBME (Tertiary butyl methyl 
ether). The mixture was once again vortexed and 
centrifuged at 2500 × g for 10 min. The organic 
phase was collected and evaporated to dryness 
at 55 °C under a gentle stream of nitrogen. The 
dried residue was reconstituted with 200 μL of 
mobile phase (acetonitrile: 25.0 mM KH2PO4, pH 
3.2 (50:50 % v/v) and vortexed for 1 min. The 
supernatant was collected into a 250 μL vial-
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Selection of complex 
 
Complexes obtained by solvent evaporation (NC-
01) and kneading method (NC-03) were in the 
form of lumps and off white in color. In case of 
freeze dried product (NC-02) texture was free 
flowing and white in color. Hence, NC-02 was 
selected for further studies based on its superior 




IR spectra of Inclusion complex (NC-02) is 
shown in Fig. 1. Observation of the IR spectra 
clearly indicates that the shape and intensity of 
peaks of NM are largely affected when it is 
complexed with β-CD. The essential peaks of 
Nelfinavir have been shifted, and there was an 
intense broad peak at 3379.40 cm-1 indicating 
possible H bonding between NM and β-CD. 
 
In vitro dissolution  
 
Rapid cumulative  release of 75-90 % was 
observed within 5 min with the NM βCD; this is 
very high compared to plain NM drug which 
released only 40 % in 90 min. NC-01-87 %, NC-
02- 95 %, NC-03- 98 %  release in 5 min.  All the 
complex formation approaches improved in vitro 
dissolution. 
 
Solubility of drug and β-CD-drug complex 
(NC-02)  
 
As NM is a basic drug, it shows ionization in 
acidic medium and is therefore soluble in low pH 
solutions. Our results also showed highest 
solubility at pH 1.2 when compared with other 
buffers of higher pH. However, highest solubility 
was observed in water as NM is in salt form.  
 
From the solubility study of both drug as well as 
Inclusion complex, it is clear that there has been 
significant increase in the solubility of drug in 
water (4.63 fold), pH 1.2 (5.32 fold) and pH 4.5 




The plasma concentration - time profile of orally 
administered NM in 0.5 % carboxy methyl 
cellulose suspension and in combination with β-
CD is shown in Figures 3 and 4 while 
corresponding pharmacokinetic parameters are 
summarized in Table 1. 
 
Fig 1: IR spectra of inclusion complex (NC-02) 
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 Fig 2: Graphical Representation of solubility of NM and NMβ-CD (NC-02) in various media 
 
Table 1: Comparison of pharmacokinetic parameters of NM and NMβ-CD complex in male rat 
 
Parameter  Plain drug (NM) NM/β-CD complex 
tmax (h) 3.000 ± 0.00 2.125 ± 0.3146* 
Cmax (ng/ml) 2031.766 ± 649.07916 3420.33 ± 593.1910* 
AUC0-∞ (ng h. ml -1) 10214.16 ± 3908.2679 20321.59 ± 4614.4340* 
AUC0-t (ng h. ml -1) 10126.42 ± 3919.6116 19909.3 ± 4546.1903* 
Lambda Z (h.-1) 0.4949 ± 0.0902 0.38675 ± 0.0227  
Clearance (ml h.-1 ) 2484.338 ± 687.8729 1117.825 ± 204.4637*  
Vd (ml/kg) 5775.763 ± 2073.3297 2492.103 ± 414.5456*  
t1/2 (hr.) 1.4858 ± 0.2344 1.81325 ± 0.1192 
MRT (h.) 4.103467 ± 0.2290 4.5809 ± 0.2396 
Absolute bioavailability (%) 18.21 36.2* 
*P ≤ 0.05; data are mean ± standard deviation (SD) 
 
 
Fig 3: Mean plasma concentration – time profile of NM in the plasma of healthy male rats (n=6), that were 
administered a single oral dose of NM 
 
Kumari et al 
Trop J Pharm Res, August 2015; 14(8): 1338  
 
 
Fig 4: Mean plasma concentration – time profile of NM in the plasma of healthy male rats (n=6), that were 
administered oral dose of NMβ-CD Complex (NC-02) 
 
The plasma drug concentration of orally 
administered NM suspended in 0.5 % CMC 
increased gradually whereas the complex 
showed rapid increase (Table 1). The addition of 
β-CD significantly improved the area under the 
plasma concentration–time curve (10214.16 ± 
3908.2679 to 20321.59 ± 4614.4340; p ≤ 0.05) 
and peak plasma concentration (2031.766 ± 
649.07916 to 3420.33 ± 593.1910 ng/ml; p ≤ 
0.05) of orally administered NM. This may be due 
to increased rate of absorption due to enhanced 
solubility of NM in almost all the tested buffers, 
which increased the dissolution rate and 
exposure of drug throughout the gastrointestinal 
tract, making it available for absorption. 
 
The presence of β-CD significantly reduced the 
total body clearance of orally administered NM 
compared with suspension. The AUC0-∞ for i.v 
administration was 1401.634 ± 480.0477 ng/ml h. 
The absolute bioavailability values of NM in rats 
administered with NM β-CD were significantly 
greater (p ≤ 0.05) than those from the 
suspension. The absolute bioavailability of NM 
was 18.2 % and had improved almost two-fold, 




The method of preparation of drug-polymer 
complexes has profound influence on the 
physical properties of the resulting complex. 
Complexes obtained by solvent evaporation (NC-
01) and kneading method (NC-03) were in the 
form of lumps and off white in color. This may be 
due to processing conditions. The freeze dried 
product (NC-02) texture was fluffy, free flowing 
and white in color. Hence further evaluation was 
carried out using the freeze dried NM β-CD 
complex. FTIR report confirmed the formation of 
NM β-CD complex. The IR spectra showed 
broadening of peak at 3379.40 cm-1 indicating 
interaction between the OH groups of 
cyclodextrin and NM due to formation of 
hydrogen bond. 
 
The saturation solubility of drug in multimedia 
(Fig 2) indicates significant enhancement in 
solubility for the NM β-CD complex. The 
dissolution profiles of inclusion complexes 
prepared by various methods show rapid 
cumulative release of 75-90 % within 5 min 
compared to plain drug release of 40 % in 90 
min.  It is apparent from studies reporting 
enhanced oral bioavailability employing 
cyclodextrins that enhancement in oral 
bioavailability is due to increase in dissolution 
kinetics and solubility. The classical Noyes 
Whitney dissolution expression is modified when 
cyclodextrin is present [16]. The presence of 
cyclodextrin in the vicinity of the dissolving drug 
particle enables the rate of dissolution to have a 
direct relation to an additional driving force: the 
difference in complex concentration at surface of 
the particle and in the bulk intestinal fluid.  
 
The complex of a poorly soluble drug is usually 
more hydrophilic and soluble than the free drug. 
Apart from this, cyclodextrin complexes are 
generally amorphous. Compared to crystalline 
drug, amorphous drug is easily broken up by 
water molecules [19]. Rapid release of the drug 
in the first few minutes when compared to the 
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pure drug could be attributed to this. The slower 
release for the remaining drug can be explained 
due to its entrapment in the host cyclodextrin 
inclusion complex. Apart from complexation, non-
inclusion phenomena such as van der Waals 
forces and hydrophobic interaction also 
contribute to formation of stable complex. 
Hydrogen bonds can be formed between drug 
molecules and hydroxyl groups on outer surface 
of cyclodextrin molecule [5]. The cyclodextrin 
molecule has glucopyranose units with 
hydrophilic exterior and an interior non-polar 
cavity. Interaction with drug leads to formation of 
the inclusion complex. 
 
The results of solubility studies show highest 
solubility at pH 1.2 when compared with other 
buffers of higher pH.  NM being a basic drug, its 
dissolution is favored at acidic pH. However, 
highest solubility was observed in water because 
of its salt form physical state. Solubilisation of 
poorly soluble drugs complexed with 
cyclodextrin, because of a rise in dissolution 
kinetics, is often mentioned as the reason for 
improved drug bioavailability when complexed 
with cyclodextrins and used for dosing [20]. 
Because pH varies throughout the 
gastrointestinal tract, pH-dependent solubility 
studies would benefit us greatly in assessing the 
oral bioavailability of NM β-CD complexes. The 
variable gastrointestinal environment can alter 
the effect that cyclodextrin eventually has on 
drug solubility. As a dosage form transits through 
the gastrointestinal tract, the changes in 
physiological environment can influence the 
dissolution kinetics of drugs, cyclodextrins and 
complexes particularly if the drug ionization is 
affected with changes in physiological pH [21]. 
The solubility study results of the inclusion 
complex showed increase in all gastrointestinal 
buffers studied thereby ensuring improved 
solubility in physiological medium as well. 
 
The pharmacokinetic studies in male Wistar rats 
showed a remarkable increase in the AUC of NM 
β-CD complex compared to plain NM. The 
enhanced of bioavailability of NM,  a BCS class 
IV drug having low solubility and low 
permeability, by complexation with β-CD can be 
explained as follows. Cyclodextrins enhance 
bioavailability of insoluble drugs by increasing 
the drug solubility, dissolution and/or drug 
permeability. Cyclodextrins increase the 
permeability of lipophilic drugs by increasing the 
dissolution efficiency thereby leading to higher 
percentage of drug being absorbed.  Because 
more of dissolved drug becomes available, it 
rapidly partitions into the membranes and gets 
absorbed. This justifies improvement of 
bioavailability of NM by β-CD because 
cyclodextrins address both solubility and 
permeability issues. 
 
Pharmacokinetic studies of NM by oral 
administration resulted in increased extent and 
rate of oral absorption when NM is complexed 
with β-CD. The increased oral bioavailability will 




Enhanced dissolution and bioavailability of NM, a 
BCS class IV drug, can be achieved via 
complexation of the drug with β-CD. There was 
no significant difference in dissolution profile 
among the inclusion complexes prepared by 
various methods. Pharmacokinetic studies in 
male Wistar rats showed distinctly different 
pharmacokinetic parameters of NM-β-CD 
compared to NM, thereby demonstrating the 
enhanced bioavailability of NM and justifying the 




The authors thank Manipal University for 




1. Pai VB, Nahata MC. Nelfinavir mesylate: A protease 
inhibitor. Ann. Pharmacother. 1999; 33(3): 325-339. 
2. Katzung BG. Basic and Clinical Pharmacology. NY: Mc 
Graw Hill Lange; 2002; p 855. 
3. Lindenberg M, Kopp S, Dressman JB. Classification of 
orally administered drugs on the World Health 
Organization Model list of Essential Medicines 
according to the biopharmaceutics classification 
system. Eur. J. Pharm. Biopharm. 2004; 58: 265–
278. 
4. Williams GC, Sinko PJ. Oral absorption of the HIV 
protease inhibitors: a current update. Adv Drug Deliv 
Rev 1999; 18; 39(1-3): 211-238. 
5. Loftsson T, Brewster ME. Pharmaceutical applications of 
cyclodextrins.  Drug solubilisation and stabilization. J. 
Pharm. Sci 1996; 85: 1017–1025. 
6. Blanchard J, Proniuk S. Some important considerations 
in the use of cyclodextrins. Pharm. Res 1999; 16: 
1796–1798. 
7. Frijlink HW, Schoonen AJM, Lerk CF. The effects of 
cyclodextrins on drug absorption.  In vitro 
observations. Int. J. Pharm. 1989; 49: 91-102. 
8. Rawata S, Jain SK. Solubility enhancement of celecoxib 
using ß-cyclodextrin inclusion complexes. Eur. J. 
Pharm. Biopharm. 2004; 57: 263–267. 
9. Kurkov SV, Loftsson T. Cyclodextrins. Int. J. Pharm. 
2013; 453: 167-180. 
Kumari et al 
Trop J Pharm Res, August 2015; 14(8): 1340  
 
10. Hiremanth SN, Godge GR, Kharia AA, Vaidya VR. 
Studies on the Preparation, Characterization and 
Solubility of β -cyclodextrin-Nelfinavir Inclusion 
complexes. J Pharm. Res. Heal. Care 2008; 2(3): 
279-284. 
11. Torne SJ, Torne JS, Vavia PR, Singh SK,  Kishore N. 
Cyclodextrin based drug delivery system of protease 
inhibitor—nelfinavir mesylate. J Inclu Phenom Macro 
2007; (57): 689-697. 
12. Anand O, Yu LX, Conner DP, Davit BM. Dissolution 
Testing for Generic Drugs: An FDA Perspective. 
AAPS J. 2011; 13(3): 328–335. 
13. Higuchi T, Connors KA, Phase solubility techniques, in: 
CN Reilly (Ed), in: Advances in Analytical Chemistry 
and Instrumentation, Wiley–Interscience, New York, 
1965,pp 117-212 . 
14. Sharma MC, Sharma S. Preparation, Physicochemical 
Characterization, Dissolution, Formulation and 
Spectroscopic studies of β-cyclodextrins Inclusion 
Complex. International Journal of Chem Tech 
Research 2011; 3(1): 104-111. 
15. Ozkan Y, Atay T, Dikmen N, Isimer A, Aboul-Enein HY. 
Improvement of water solubility and in vitro 
dissolution rate of gliclazide by complexation with β -
cyclodextrin. Pharm Acta Helv 2000; 74: 365-370. 
16. Talegaonkar S, Khan AY, Khar RK, Ahmad FJ, Khan ZI. 
Development and Characterization of Paracetamol 
Complexes with Hydroxypropyl-β-Cyclodextrin. Iran. 
J. Pharm. Res 2007;    6(2): 95-99. 
17. Aleema O, Kuchekar B, Pore Y, Late S. Effect of β-
cyclodextrin and hydroxypropyl β-cyclodextrin 
complexation on physicochemical properties and 
antimicrobial activity of cefdinir. J.  Pharma. Biomed. 
Anal 2008; 47: 535-540. 
18. Validation of Analytical Procedures: Text and 




19. Rebecca L, Carrier Lee A, Miller, Ahmed I. The utility of 
cyclodextrins in enhancing the oral bioavailability. J. 
Control. Release 2007; 123: 78–99. 
20. Soliman OAE, Kimura K, Hirayama F, Uekama K, El-
Sabbagh HM, El-Gawad AEGHA, Hashim FM. 
Amorphous spironolactone-hydroxypropylated 
cyclodextrin complexes with superior dissolution and 
oral bioavailability. Int. J. Pharm. 1997; 149: 73-83. 
21. Savolainen J, Järvinen K, Taipale H, Jarho P, Loftsson T, 
Järvinen T. Co administration of a water soluble 
polymer increases the usefulness of cyclodextrins in 
solid oral dosage forms. Pharm. Res. 1998; 15(11): 
1696-1701. 
 
